Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer

被引：0
|
作者：
Chan, Nancy
Lu, Shou-en
Wang, Yue
Riedlinger, Gregory M.
Omene, Coral
George, Mridula
Malhotra, Jyoti
Kowzun, Maria
Eladoumikdachi, Firas G.
Potdevin, Lindsay B.
Kumar, Shicha
Matsuda, Kant
Desai, Shruti
Patel, Nayana
Toppmeyer, Deborah L.
Ganesan, Shridar
Hirshfield, Kim
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-15
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of triple negative breast cancer
    Chan, N.
    Riedlinger, G. M.
    Lu, S-e
    Pham, K. T.
    Kirstein, L. J.
    Eladoumikdachi, F. G.
    George, M. A.
    Potdevin, L. B.
    Kowzun, M. J.
    Desai, S. A.
    Tang, D. M.
    Omene, C. O.
    Wong, S. T.
    Rodriguez-Rust, L.
    Kumar, S.
    Kearney, T. J.
    Liu, C.
    Ganesan, S.
    Toppmeyer, D. L.
    Hirshfield, K. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Role of Carboplatin in the Treatment of Triple Negative Early-Stage Breast Cancer
    Valsecchi, Matias E.
    Kimmey, Gerrit
    Bir, Arvinder
    Silbermins, Damian
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) : 101 - 110
  • [3] Carboplatin for early triple- negative breast cancer?
    Valero, Vicente
    LANCET ONCOLOGY, 2014, 15 (07): : 676 - 678
  • [4] Pembrolizumab in the neoadjuvant Treatment of early triple-negative Breast Cancer
    Dierks, Friederike
    Pietsch, Elisabeth
    Dunst, Juergen
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (09) : 841 - 843
  • [5] Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer
    Yu, Zhigang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5
  • [6] Applicability of carboplatin containing neoadjuvant treatment regimen in triple negative early breast cancer patients - a single center experience
    De Pellegrin, L.
    Hofer, S.
    Weiss, R.
    Zapf, K.
    Gampenrieder, S. P.
    Hauser-Kronberger, C.
    Reitsamer, R.
    Greil, R.
    Rinnerthaler, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 158 - 159
  • [7] Advancing Treatment for Triple Negative Breast Cancer: Liposomal Oncolytic Adenovirus as a Novel Neoadjuvant Therapy
    Khan, Sohini
    Shah, Jaimin R.
    Dong, Tao
    Phung, Abraham T.
    Aisagbonhi, Omonigho
    Trogler, William C.
    Blair, Sarah L.
    Kummel, Andrew C.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S118 - S119
  • [8] Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?
    Foukakis, T.
    ANNALS OF ONCOLOGY, 2018, 29 (12) : 2278 - 2280
  • [9] Neoadjuvant eribulin in early triple negative breast cancer
    Naito, Y.
    Yonemori, K.
    Yamamoto, H.
    Takahashi, M.
    Nakamura, R.
    Masuda, N.
    Aogi, K.
    Yamanaka, T.
    Ito, Y.
    Yoshida, A.
    Tsuda, H.
    Kuchiba, A.
    Hata, T.
    Tamura, K.
    Fujiwara, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S97 - S98
  • [10] Phase II single arm study of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy
    Murthy, Rashmi K.
    Ueno, Naoto T.
    Symmans, William F.
    Litton, Jennifer K.
    Arun, Banu K.
    Ibrahim, Nuhad K.
    Alvarez, Ricardo H.
    Gilcrease, Michael Z.
    Valero, Vicente
    Tripathy, Debasish
    Moulder, Stacy L.
    CANCER RESEARCH, 2015, 75
12345